Described herein are silicon based conjugates capable of delivering one or more payload moieties to a target cell or tissue. Contemplated conjugates may include a silicon-heteroatom core, one or more optional catalytic moieties, a targeting moiety that permits accumulation of the conjugate within a target cell or tissue, one or more payload moieties (e.g., a therapeutic agent or imaging agent), and two or more non-interfering moieties covalently bound to the silicon-heteroatom core.

The present invention relates to a Bicycle toxin conjugate BT5528, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof, and uses thereof.

The present invention relates to a Bicycle toxin conjugate BT5528, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof, and uses thereof.

Disclosed herein are ACE2-Fc fusion polypeptides that contain at least one binding site for a spike protein of a coronavirus and methods of using such for therapeutic and/or diagnostic purposes. Also provided herein are methods for producing such fusion polypeptides.

Provided herein are methods of preparing polyglutamated compounds, such as polyglutamated antifolates, and/or pharmaceutical compositions such as liposomal compositions comprising the same, Also provided herein are substantially pure polyglutamated compounds, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition such as liposomal composition comprising the same. The present disclosure further provides methods of using the polyglutamated compounds and compositions to treat diseases including hyperproliferative diseases such as cancer, disorders of the immune system such as rheumatoid arthritis, and infectious diseases such as HIV, malaria, and schistomiasis.

The present invention relates to a physiologically active substance to which a biotin moiety is bound; and a composition for oral administration comprising same. A physiologically active substance to which a biotin moiety is bound has excellent oral absorption into the body.

The present invention relates to a physiologically active substance to which a biotin moiety is bound; and a composition for oral administration comprising same. A physiologically active substance to which a biotin moiety is bound has excellent oral absorption into the body.

The present disclosure relates to conjugates for delivering therapeutics across the blood brain barrier (BBB) and more particularly to conjugates comprising at least one BBB-shuttling VNAR domain operably linked to a neurotrophic agonist antibody (NAAb), with the conjugate being capable of uptake across a mammalian blood brain barrier (BBB) in a therapeutically-effective amount. These conjugates are useful for treating neurodegenerative diseases, conditions which responds to activation of a neurotrophin receptor as well as for stimulating neuronal survival, growth, repair or regeneration.

The present disclosure provides macrocyclic compounds inspired by the immunophilin ligand family of natural products FK506 and rapamycin. The generation of a Rapafucin library of macrocyles that contain FK506 and rapamycin binding domains should have great potential as new leads for developing drugs to be used for treating diseases.

The present disclosure provides macrocyclic compounds inspired by the immunophilin ligand family of natural products FK506 and rapamycin. The generation of a Rapafucin library of macrocyles that contain FK506 and rapamycin binding domains should have great potential as new leads for developing drugs to be used for treating diseases.